UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): APRIL 22, 2003
THE MEDICINES COMPANY
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 000-31191 04-3324394
---------------------------- ------------ -------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
8 CAMPUS DRIVE
PARSIPPANY, NEW JERSEY 07054
---------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (973) 656-1616
5 SYLVAN WAY, PARSIPPANY, NEW JERSEY 07054
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press release dated April 22, 2003 entitled "The Medicines
Company Reports First Quarter 2003 Financial Results."
ITEM 9. REGULATION FD DISCLOSURE (INFORMATION FURNISHED PURSUANT TO ITEM 12,
"DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION").
On April 22, 2003, The Medicines Company (the "Company") announced its
financial results for the quarter ended March 31, 2003. The full text of the
press release issued in connection with the announcement is filed as Exhibit
99.1 to this Current Report on Form 8-K.
In accordance with the procedural guidance in SEC Release No. 33-8216, the
information in this Form 8-K and the Exhibit attached hereto is being furnished
under "Item 9. Regulation FD Disclosure" rather than under "Item 12. Disclosure
of Results of Operations and Financial Condition." The information shall be
deemed incorporated by reference in any registration statement previously or
subsequently filed by the Company under the Securities Act of 1933, as amended,
except to the extent that such information is superceded by information as of a
subsequent date that is included or incorporated by reference into such
registration statement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THE MEDICINES COMPANY
Date: April 22, 2003 By: /s/ Steven H. Koehler
--------------------------
Steven H. Koehler
Vice President and Chief Financial
Officer
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release dated April 22, 2003 entitled "The Medicines
Company Reports First Quarter 2003 Financial Results."